{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T21:09:21Z","timestamp":1788728961701,"version":"build-2803163510"},"reference-count":280,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.pharmthera.2026.109102","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:49:20Z","timestamp":1787294960000},"page":"109102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Thrombin generation and the pharmacodynamics of oral anticoagulants"],"prefix":"10.1016","volume":"287","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2405-7912","authenticated-orcid":false,"given":"Joseph R.","family":"Shaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3951-2911","authenticated-orcid":false,"given":"Dylan","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2512-7494","authenticated-orcid":false,"given":"Julie","family":"Vassart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6701-9417","authenticated-orcid":false,"given":"Michael","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1322-9368","authenticated-orcid":false,"given":"Lana A.","family":"Castellucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8296-2972","authenticated-orcid":false,"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0504-3064","authenticated-orcid":false,"given":"Paul Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7644-5298","authenticated-orcid":false,"given":"Jonathan","family":"Douxfils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6947-6099","authenticated-orcid":false,"given":"Francois","family":"Mullier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8304-6423","authenticated-orcid":false,"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6445-582X","authenticated-orcid":false,"given":"Jean M.","family":"Connors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Spronk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3766-4962","authenticated-orcid":false,"given":"Jerrold H.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7796-4463","authenticated-orcid":false,"given":"Hugo","family":"ten Cate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb0005","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1046\/j.1538-7836.2003.00127.x","article-title":"Predicting the pharmacology of thrombin inhibitors","volume":"1","author":"Adams","year":"2003","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"17","key":"10.1016\/j.pharmthera.2026.109102_bb0010","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109102_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtha.2024.12.032","article-title":"Peak and trough concentrations of apixaban and rivaroxaban in adult patients: A systematic review and meta-analysis","author":"Almalbis","year":"2025","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109102_bb0020","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1111\/j.1538-7836.2007.02606.x","article-title":"Relationship between thrombin generation and international normalized ratio in patients receiving oral vitamin K antagonist therapy","volume":"5","author":"Altman","year":"2007","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"22","key":"10.1016\/j.pharmthera.2026.109102_bb0025","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1001\/jama.2021.20552","article-title":"Heterogeneity of treatment effect: Estimating how the effects of interventions vary across individuals","volume":"326","author":"Angus","year":"2021","journal-title":"JAMA"},{"issue":"6 Suppl","key":"10.1016\/j.pharmthera.2026.109102_bb0030","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb0035","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1161\/01.CIR.90.4.1624","article-title":"Hirudin in acute myocardial infarction. Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial","volume":"90","author":"Antman","year":"1994","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109102_bb0040","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.thromres.2014.11.037","article-title":"Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism","volume":"135","author":"Arachchillage","year":"2015","journal-title":"Thrombosis Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109102_bb0045","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/rth2.12044","article-title":"Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay","volume":"1","author":"Artang","year":"2017","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"15","key":"10.1016\/j.pharmthera.2026.109102_bb0050","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2010.32.8294","article-title":"Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: Results from the Vienna cancer and thrombosis study","volume":"29","author":"Ay","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb0055","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2141.2005.05612.x","article-title":"The measurement and application of thrombin generation","volume":"130","author":"Baglin","year":"2005","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109102_bb0060","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/FTD.0b013e31818b0d71","article-title":"Differential effects of factor IIa inhibitors on the endogenous thrombin potential","volume":"30","author":"Beilfuss","year":"2008","journal-title":"Therapeutic Drug Monitoring"},{"issue":"101653388","key":"10.1016\/j.pharmthera.2026.109102_bb0065","article-title":"Serial thrombin generation and exploration of alternative anticoagulants in critically ill COVID-19 patients: Observations from Maastricht intensive care COVID cohort","volume":"9","author":"van de Berg","year":"2022","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb0070","article-title":"Thrombin generation in a patient with triple positive antiphospholipid syndrome treated with three different anticoagulants","volume":"59","author":"Bergstrom","year":"2020","journal-title":"Transfusion and Apheresis Science: Official Journal of the World Apheresis Association: Official Journal of the European Society for Haemapheresis"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109102_bb0075","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1055\/s-0040-1715899","article-title":"Tissue factor-independent coagulation correlates with clinical phenotype in factor XI deficiency and replacement therapy","volume":"121","author":"Bertaggia Calderara","year":"2021","journal-title":"Thrombosis and Haemostasis"},{"issue":"16","key":"10.1016\/j.pharmthera.2026.109102_bb0080","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1161\/CIRCULATIONAHA.123.063946","article-title":"Bivalirudin versus heparin during PCI in NSTEMI: Individual patient data meta-analysis of large randomized trials","volume":"148","author":"Bikdeli","year":"2023","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb0085","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3324\/haematol.2012.073601","article-title":"Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation","volume":"98","author":"Bloemen","year":"2013","journal-title":"Haematologica"},{"issue":"0326377","key":"10.1016\/j.pharmthera.2026.109102_bb0090","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.thromres.2018.10.005","article-title":"The anticoagulant effect of dabigatran is reflected in the lag time and time-to-peak, but not in the endogenous thrombin potential or peak, of thrombin generation","volume":"171","author":"Bloemen","year":"2018","journal-title":"Thrombosis Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176967","article-title":"Prediction of bleeding risk in patients taking vitamin K antagonists using thrombin generation testing","volume":"12","author":"Bloemen","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb0100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/jcph.2184","article-title":"Direct Oral anticoagulants: An updated systematic review of their clinical pharmacology and clinical effectiveness and safety in patients with nonvalvular atrial fibrillation","volume":"63","author":"Bortman","year":"2023","journal-title":"Journal of Clinical Pharmacology"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109102_bb0105","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1016\/j.jtha.2023.06.009","article-title":"Contact system and intrinsic pathway activation in patients with advanced pancreatic cancer: A prospective cohort study","volume":"21","author":"Bosch","year":"2023","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2026.109102_bb0110","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/1749-8090-8-154","article-title":"Preoperative thrombin generation is predictive for the risk of blood loss after cardiac surgery: a research article","volume":"8","author":"Bosch","year":"2013","journal-title":"Journal of Cardiothoracic Surgery"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb0115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00001721-200401000-00005","article-title":"Inhibition of thrombin-induced feedback activation of factor V: A potential pathway for inhibition of thrombin generation by melagatran","volume":"15","author":"Bostrom","year":"2004","journal-title":"Blood Coagulation & Fibrinolysis: an International Journal in Haemostasis and Thrombosis"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109102_bb0120","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1160\/TH15-12-0927","article-title":"Inactivated antithrombins as fondaparinux antidotes: A promising alternative to haemostatic agents as assessed in vitro in a thrombin-generation assay","volume":"116","author":"Bourti","year":"2016","journal-title":"Thrombosis and Haemostasis"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109102_bb0125","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1160\/TH08-07-0465","article-title":"Thrombin generation test in patients under anticoagulant therapy with vitamin K antagonists","volume":"101","author":"Brocal","year":"2009","journal-title":"Thrombosis and Haemostasis"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109102_bb0130","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1016\/j.jtha.2025.05.030","article-title":"Interferences associated with the factor XIa inhibitors asundexian and milvexian in routine and specialized coagulation assays and their removal by activated charcoal-based adsorbents","volume":"23","author":"Buckley","year":"2025","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"27","key":"10.1016\/j.pharmthera.2026.109102_bb0135","doi-asserted-by":"crossref","first-page":"18569","DOI":"10.1074\/jbc.M600752200","article-title":"The structural integrity of anion binding exosite I of thrombin is required and sufficient for timely cleavage and activation of factor V and factor VIII","volume":"281","author":"Bukys","year":"2006","journal-title":"The Journal of Biological Chemistry"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109102_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102600","article-title":"The anticoagulant effects of milvexian, a novel small molecule factor XIa inhibitor, are neutralized by activated prothrombin complex concentrates and recombinant factor VIIa in human plasma and whole blood in vitro","volume":"8","author":"Bunce","year":"2024","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109102_bb0145","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1111\/j.1538-7836.2012.04892.x","article-title":"Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: Contribution of the serpin-independent mechanism","volume":"10","author":"Buyue","year":"2012","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109102_bb0150","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: A clinical pharmacokinetic and Pharmacodynamic review","volume":"58","author":"Byon","year":"2019","journal-title":"Clinical Pharmacokinetics"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb0155","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct Oral anticoagulants versus warfarin in patients with atrial fibrillation: Patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109102_bb0160","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJMoa2510703","article-title":"Bleeding risk with Apixaban vs. rivaroxaban in acute venous thromboembolism","volume":"394","author":"Castellucci Lana","year":"2026","journal-title":"The New England Journal of Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109102_bb0165","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13895","article-title":"Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data","volume":"17","author":"Chen","year":"2024","journal-title":"Clinical and Translational Science"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb0170","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/16078454.2022.2043573","article-title":"A correlation of thrombin generation assay and clot waveform analysis in patients on warfarin","volume":"27","author":"Cheong","year":"2022","journal-title":"Hematology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109102_bb0175","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.thromres.2006.03.004","article-title":"The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT","volume":"119","author":"Cimenti","year":"2007","journal-title":"Thrombosis Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109102_bb0180","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1538-7836.2010.04146.x","article-title":"Assessment of thrombin generation measured before and after cardiopulmonary bypass surgery and its association with postoperative bleeding","volume":"9","author":"Coakley","year":"2011","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109102_bb0185","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): A randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematology"},{"issue":"20","key":"10.1016\/j.pharmthera.2026.109102_bb0190","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/eurheartj\/eht039","article-title":"Betrixaban compared with warfarin in patients with atrial fibrillation: Results of a phase 2, randomized, dose-ranging study (explore-Xa)","volume":"34","author":"Connolly","year":"2013","journal-title":"European Heart Journal"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109102_bb0195","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"The New England Journal of Medicine"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109102_bb0200","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in rheumatic heart disease-associated atrial fibrillation","volume":"387","author":"Connolly","year":"2022","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109102_bb0205","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1538-7836.2007.02500.x","article-title":"The central role of thrombin in hemostasis","volume":"5","author":"Crawley","year":"2007","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109102_bb0210","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11239-012-0857-9","article-title":"Dabigatran attenuates thrombin generation to a lesser extent than warfarin: Could this explain their differential effects on intracranial hemorrhage and myocardial infarction?","volume":"35","author":"Dale","year":"2013","journal-title":"Journal of Thrombosis and Thrombolysis"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109102_bb0215","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/j.1538-7836.2008.02964.x","article-title":"Comparison of the capacities of two prothrombin complex concentrates to restore thrombin generation in plasma from orally anticoagulated patients: An in vitro study","volume":"6","author":"Dargaud","year":"2008","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109102_bb0220","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/jth.12244","article-title":"Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: The effect of low factor IX levels","volume":"11","author":"Dargaud","year":"2013","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109102_bb0225","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2141.2007.06785.x","article-title":"Effect of standardization and normalization on imprecision of calibrated automated thrombography: An international multicentre study","volume":"139","author":"Dargaud","year":"2007","journal-title":"British Journal of Haematology"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109102_bb0230","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/jth.13743","article-title":"Subcommittee on Factor VIII FcI, and Rare Coagulation Disorders. Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH","volume":"15","author":"Dargaud","year":"2017","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2026.109102_bb0235","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.thromres.2017.04.003","article-title":"A prospective study of rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2)","volume":"162","author":"Davies","year":"2018","journal-title":"Thrombosis Research"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109102_bb0240","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1111\/jth.15529","article-title":"Thrombin generation assays are versatile tools in blood coagulation analysis: A review of technical features, and applications from research to laboratory routine","volume":"19","author":"Depasse","year":"2021","journal-title":"J Thromb Haemost."},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb0245","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1538-7836.2007.02824.x","article-title":"Coagulation factors and the protein C system as determinants of thrombin generation in a normal population","volume":"6","author":"Dielis","year":"2008","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109102_bb0250","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/j.1538-7836.2004.00798.x","article-title":"Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time","volume":"2","author":"al Dieri R, Alban S, B\u00e9guin S, Hemker HC.","year":"2004","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109102_bb0255","first-page":"505","article-title":"Differential effect of direct oral anticoagulants on thrombin generation and fibrinolysis in patients with atrial fibrillation and venous thromboembolism","volume":"20","author":"Dirienzo","year":"2022","journal-title":"Blood Transfusion"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb0260","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/jth.15642","article-title":"Thrombin in complex with dabigatran can still interact with PAR-1 via exosite-I and instigate loss of vascular integrity","volume":"20","author":"Dolleman","year":"2022","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109102_bb0265","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/jth.13912","article-title":"Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians","volume":"16","author":"Douxfils","year":"2018","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109102_bb0270","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1160\/th15-05-0415","article-title":"Impact on routine and specific coagulation assays. A practical laboratory guide","volume":"115","author":"Douxfils","year":"2016","journal-title":"Thrombosis and Haemostasis"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109102_bb0275","first-page":"283","article-title":"Impact of apixaban on routine and specific coagulation assays: A practical laboratory guide","volume":"110","author":"Douxfils","year":"2013","journal-title":"Thrombosis and Haemostasis"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109102_bb0280","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/jth.14470","article-title":"Assessment of the analytical performances and sample stability on ST Genesia system using the STG-DrugScreen application","volume":"17","author":"Douxfils","year":"2019","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109102_bb0285","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.thromres.2012.09.004","article-title":"Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literature","volume":"130","author":"Douxfils","year":"2012","journal-title":"Thrombosis Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb0290","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1160\/TH11-11-0804","article-title":"Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate","volume":"107","author":"Douxfils","year":"2012","journal-title":"Thrombosis and Haemostasis"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb0295","first-page":"1087","article-title":"Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis","volume":"134","author":"Drake","year":"1989","journal-title":"The American Journal of Pathology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb0300","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11239-020-02126-3","article-title":"Thrombin generation and other hemostatic parameters in patients with atrial fibrillation in use of warfarin or rivaroxaban","volume":"51","author":"Duarte","year":"2021","journal-title":"Journal of Thrombosis and Thrombolysis"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109102_bb0305","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.thromres.2015.03.030","article-title":"Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome","volume":"135","author":"Efthymiou","year":"2015","journal-title":"Thrombosis Research"},{"issue":"13","key":"10.1016\/j.pharmthera.2026.109102_bb0310","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb0315","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jamacardio.2017.0364","article-title":"Laboratory monitoring of non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation: A review","volume":"2","author":"Eikelboom","year":"2017","journal-title":"JAMA Cardiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb0320","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1111\/ijlh.13356","article-title":"Are the DOAC plasma level thresholds appropriate for clinical decision-making? A reappraisal using thrombin generation testing","volume":"43","author":"Evrard","year":"2021","journal-title":"International Journal of Laboratory Hematology"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109102_bb0325","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1016\/j.jtha.2025.05.032","article-title":"DOAC-stop reverses the anticoagulant effect of asundexian and milvexian","volume":"23","author":"Fitzpatrick","year":"2025","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb0330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054728","article-title":"From principle to practice: Bridging the gap in patient profiling","volume":"8","author":"Foley","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb0335","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1055\/a-1981-1763","article-title":"Assessment of DOAC in GEriatrics (adage study): Rivaroxaban\/Apixaban concentrations and thrombin generation profiles in NVAF very elderly patients","volume":"123","author":"Foulon-Pinto","year":"2023","journal-title":"Thrombosis and Haemostasis"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.102969","article-title":"Fibrinography and thrombography (thrombodynamics-4D) in atrial fibrillation assessment of direct oral anticoagulants in geriatrics patients aged 80 years and older receiving direct oral anticoagulant therapy","volume":"9","author":"Foulon-Pinto","year":"2025","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb0345","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/ijlh.13443","article-title":"Study of thrombin generation with St Genesia to evaluate xaban pharmacodynamics: Analytical performances over 18 months","volume":"43","author":"Foulon-Pinto","year":"2021","journal-title":"International Journal of Laboratory Hematology"},{"issue":"101564865","key":"10.1016\/j.pharmthera.2026.109102_bb0350","first-page":"153","article-title":"Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects","volume":"10","author":"Frost","year":"2018","journal-title":"Clinical Pharmacology: Advances and Applications"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109102_bb0355","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.thromres.2015.06.034","article-title":"Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin","volume":"136","author":"Furugohri","year":"2015","journal-title":"Thrombosis Research"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109102_bb0360","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1538-7836.2009.03435.x","article-title":"Optimizing warfarin reversal--an ex vivo study","volume":"7","author":"Gatt","year":"2009","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109102_bb0365","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1365-2141.2008.07279.x","article-title":"Wide variation in thrombin generation in patients with atrial fibrillation and therapeutic international normalized ratio is not due to inflammation","volume":"142","author":"Gatt","year":"2008","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109102_bb0370","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1160\/TH07-05-0357","article-title":"Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro","volume":"100","author":"Gatt","year":"2008","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2026.109102_bb0375","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1075121","article-title":"Application of the thrombin generation assay in patients with antiphospholipid syndrome: A systematic review of the literature","volume":"10","author":"Gehlen","year":"2023","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109102_bb0380","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1160\/TH03-11-0694","article-title":"In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile","volume":"92","author":"Gerotziafas","year":"2017","journal-title":"Thrombosis and Haemostasis"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109102_bb0385","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00001721-200403000-00006","article-title":"Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma","volume":"15","author":"Gerotziafas","year":"2004","journal-title":"Blood Coagulation & Fibrinolysis"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb0390","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1160\/TH08-10-0653","article-title":"Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin","volume":"102","author":"Gerotziafas","year":"2009","journal-title":"Thrombosis and Haemostasis"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb0395","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/j.1538-7836.2007.02429.x","article-title":"In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban","volume":"5","author":"Gerotziafas","year":"2007","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb0400","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1538-7836.2007.02477.x","article-title":"Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation","volume":"5","author":"Gerotziafas","year":"2007","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2026.109102_bb0405","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ahj.2025.02.011","article-title":"Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS)","volume":"285","author":"Gibson","year":"2025","journal-title":"American Heart Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb0410","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12959-021-00312-8","article-title":"Calibrated automated thrombogram II: Removing barriers for thrombin generation measurements","volume":"19","author":"Giesen","year":"2021","journal-title":"Thrombosis Journal"},{"issue":"22","key":"10.1016\/j.pharmthera.2026.109102_bb0415","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109102_bb0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2017.05.001","article-title":"Abnormal uterine bleeding in women receiving direct oral anticoagulants for the treatment of venous thromboembolism","volume":"93-95","author":"Godin","year":"2017","journal-title":"Vascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109102_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtha.2025.06.031","article-title":"Plasma levels measurement of the four direct oral anticoagulants in patients with atrial fibrillation at the time of acute thromboembolic and bleeding events","author":"Godino","year":"2025","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109102_bb0430","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.jtha.2025.02.029","article-title":"Activated factor XI-antithrombin and thrombin-antithrombin complexes in the prediction of venous thromboembolism and mortality in patients with non-small-cell lung cancer","volume":"23","author":"Gomez-Rosas","year":"2025","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2026.109102_bb0435","series-title":"Mechanistic evidence in evidence-based medicine: A conceptual framework","author":"Goodman","year":"2013"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb0440","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.jtha.2025.02.025","article-title":"Anticoagulant drugs targeting factor XI\/XIa and coagulation tests: We urgently need reliable pharmacodynamic data","volume":"23","author":"Gouin-Thibault","year":"2025","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb0445","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1538-7836.2006.01830.x","article-title":"Inhibitors of blood coagulation factors Xa and IIa synergize to reduce thrombus weight and thrombin generation in vivo and in vitro","volume":"4","author":"Gould","year":"2006","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109102_bb0450","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"The New England Journal of Medicine"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109102_bb0455","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of factor XI inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb0460","first-page":"253","article-title":"Adapt or die: How the pandemic made the shift from EBM to EBM+ more urgent. BMJ","volume":"27","author":"Greenhalgh","year":"2022","journal-title":"Evidence-Based Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109102_bb0465","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood.V96.3.846","article-title":"Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range","volume":"96","author":"Greinacher","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109102_bb0470","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/01.CIR.100.6.587","article-title":"Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-associated thrombocytopenia study (HAT) investigators","volume":"100","author":"Greinacher","year":"1999","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb0475","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/01.CIR.99.1.73","article-title":"Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study","volume":"99","author":"Greinacher","year":"1999","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb0480","first-page":"819","article-title":"The direct thrombin inhibitor hirudin","volume":"99","author":"Greinacher","year":"2008","journal-title":"Thrombosis and Haemostasis"},{"issue":"101563288","key":"10.1016\/j.pharmthera.2026.109102_bb0485","article-title":"The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency","volume":"6","author":"Gribkova","year":"2016","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb0490","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jtha.2022.10.020","article-title":"Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro","volume":"21","author":"Guan","year":"2023","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb0495","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1161\/01.CIR.90.4.1631","article-title":"Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The global use of strategies to open occluded coronary arteries","volume":"90","author":"GUSTO IIa Investigators","year":"1994","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb0500","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.thromres.2010.07.024","article-title":"Inter-individual variability of effect of 7 low molecular weight antithrombin-dependent anticoagulants studied in vitro with calibrated automated thrombography","volume":"127","author":"Hacquard","year":"2011","journal-title":"Thrombosis Research"},{"issue":"13","key":"10.1016\/j.pharmthera.2026.109102_bb0505","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/CIRCULATIONAHA.110.004424","article-title":"Dabigatran Etexilate","volume":"123","author":"Hankey","year":"2011","journal-title":"Circulation"},{"issue":"101170508","key":"10.1016\/j.pharmthera.2026.109102_bb0510","article-title":"Effect of heparins, direct oral anticoagulants, and factor XII\/factor XI inhibitors on catheter-initiated thrombin generation in platelet-rich plasma: An in vitro study","author":"Hardy","year":"2025","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109102_bb0515","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1016\/j.jtha.2025.07.027","article-title":"Laboratory testing of factor XI inhibitors: Methodological challenges remain","volume":"23","author":"Hardy","year":"2025","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb0520","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1055\/s-0039-1700545","article-title":"Accuracy of a rapid diagnostic test for the presence of direct oral factor Xa or thrombin inhibitors in urine-a multicenter trial","volume":"120","author":"Harenberg","year":"2020","journal-title":"Thrombosis and Haemostasis"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109102_bb0525","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa","volume":"20","author":"Heitmeier","year":"2022","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109102_bb0530","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/rth2.12497","article-title":"Anticoagulated patients exhibit intact endogenous thrombin potential using ST Genesia unlike the calibrated automated thrombogram","volume":"5","author":"Helin","year":"2021","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109102_bb0535","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1182\/blood-2015-05-643403","article-title":"Thrombin generation: Biochemical possibilities and clinical reality","volume":"126","author":"Hemker","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb0540","first-page":"747","article-title":"Phenotyping the clotting system","volume":"84","author":"Hemker","year":"2000","journal-title":"Thrombosis and Haemostasis"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb0545","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"Hemker","year":"2003","journal-title":"Pathophysiology of Haemostasis and Thrombosis"},{"issue":"2 Suppl","key":"10.1016\/j.pharmthera.2026.109102_bb0550","doi-asserted-by":"crossref","first-page":"e152S","DOI":"10.1378\/chest.11-2295","article-title":"Evidence-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Holbrook","year":"2012","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109102_bb0555","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","article-title":"Systematic overview of warfarin and its drug and food interactions","volume":"165","author":"Holbrook","year":"2005","journal-title":"Archives of Internal Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb0560","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/jama.296.4.397","article-title":"Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation","volume":"296","author":"Hron","year":"2006","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109102_bb0565","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1111\/jth.14226","article-title":"Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism","volume":"16","author":"Huisman","year":"2018","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb0570","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052590","article-title":"Thrombin-Fibrin(ogen) interactions, host defense and risk of thrombosis","volume":"22","author":"Hulshof","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb0575","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1538-7933.2004.00649.x","article-title":"Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis","volume":"2","author":"Ieko","year":"2004","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109102_bb0580","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/jth.12102","article-title":"Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis","volume":"11","author":"Incampo","year":"2013","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109102_bb0585","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJM199609123351103","article-title":"A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes","volume":"335","author":"investigators GUoStOOCAGI.","year":"1996","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109102_bb0590","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.athoracsur.2019.10.091","article-title":"Rivaroxaban and dabigatran for suppression of mechanical heart valve-induced thrombin generation","volume":"110","author":"Jaffer","year":"2020","journal-title":"The Annals of Thoracic Surgery"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109102_bb0595","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002322","article-title":"Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation","volume":"4","author":"Jaffer","year":"2015","journal-title":"Journal of the American Heart Association"},{"key":"10.1016\/j.pharmthera.2026.109102_bb0600","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ahj.2024.08.011","article-title":"Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design","volume":"277","author":"Jain","year":"2024","journal-title":"American Heart Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb0605","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and Management of Atrial Fibrillation: A report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb0610","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/jth.13549","article-title":"During warfarin induction, the Fiix-prothrombin time reflects the anticoagulation level better than the standard prothrombin time","volume":"15","author":"Jonsson","year":"2017","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb0615","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1160\/TH14-10-0877","article-title":"Association rate constants rationalise the pharmacodynamics of apixaban and rivaroxaban","volume":"114","author":"Jourdi","year":"2015","journal-title":"Thrombosis and Haemostasis"},{"issue":"0326377","key":"10.1016\/j.pharmthera.2026.109102_bb0620","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.thromres.2016.03.005","article-title":"A direct thrombin inhibitor suppresses protein C activation and factor Va degradation in human plasma: Possible mechanisms of paradoxical enhancement of thrombin generation","volume":"141","author":"Kamisato","year":"2016","journal-title":"Thrombosis Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb0625","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.12.020","article-title":"Characteristics of symptomatic intracerebral hemorrhage in patient receiving direct oral anticoagulants: Comparison with warfarin","volume":"27","author":"Kawabori","year":"2018","journal-title":"Journal of Stroke and Cerebrovascular Diseases"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb0630","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cvr\/cvy272","article-title":"The prothrombotic state in atrial fibrillation: Pathophysiological and management implications","volume":"115","author":"Khan","year":"2019","journal-title":"Cardiovascular Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109102_bb0635","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1055\/s-0038-1649507","article-title":"Mechanistic basis for the differential effects of rivaroxaban and apixaban on global tests of coagulation","volume":"2","author":"Kim","year":"2018","journal-title":"TH Open: Companion Journal to Thrombosis and Haemostasis"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb0640","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/rth2.12048","article-title":"A review of commercially available thrombin generation assays","volume":"2","author":"Kintigh","year":"2018","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2026.109102_bb0645","article-title":"Antiphospholipid syndrome: Advances in diagnosis, pathogenesis, and management","volume":"380","author":"Knight","year":"2023","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109102_bb0650","first-page":"1012","article-title":"Combined effects of eptifibatide and anticoagulants: Differences between LMWH and UH or rH in thrombin generation inhibition but not in platelet aggregation inhibition","volume":"88","author":"Koestenberger","year":"2002","journal-title":"Thrombosis and Haemostasis"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb0655","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/jth.13674","article-title":"Comparing thrombin generation in patients with hemophilia a and patients on vitamin K antagonists","volume":"15","author":"de Koning","year":"2017","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109102_bb0660","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1160\/TH09-12-0817","article-title":"Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding","volume":"104","author":"Konishi","year":"2010","journal-title":"Thrombosis and Haemostasis"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109102_bb0665","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1111\/j.1538-7836.2007.02613.x","article-title":"A pilot study of central venous catheter survival in cancer patients using low molecular weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study)","volume":"5","author":"Kovacs","year":"2007","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109102_bb0670","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/jth.12798","article-title":"The balance of pro- and anticoagulant processes underlying thrombin generation","volume":"13","author":"Kremers","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109102_bb0675","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/bloodadvances.2018018036","article-title":"Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin","volume":"2","author":"Kremers","year":"2018","journal-title":"Blood Advances"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109102_bb0680","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1111\/jth.13801","article-title":"Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: A randomized crossover study","volume":"15","author":"Kreutz","year":"2017","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"24","key":"10.1016\/j.pharmthera.2026.109102_bb0685","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2015.5739","article-title":"Dosing recommendations for new oral anticoagulants","volume":"313","author":"Kreuzer","year":"2015","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109102_bb0690","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1111\/bcp.15230","article-title":"Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple-dose study","volume":"88","author":"Kubitza","year":"2022","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109102_bb0695","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.bpj.2018.11.009","article-title":"Sensitivity and robustness of spatially dependent thrombin generation and fibrin clot propagation","volume":"115","author":"Kuprash","year":"2018","journal-title":"Biophysical Journal"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb0700","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/1076029614564209","article-title":"Laboratory assessment of the anticoagulant activity of dabigatran","volume":"21","author":"Kyriakou","year":"2015","journal-title":"Clinical and Applied Thrombosis\/Hemostasis: Official Journal of the International Academy of Clinical and Applied Thrombosis\/Hemostasis"},{"issue":"9_suppl","key":"10.1016\/j.pharmthera.2026.109102_bb0705","doi-asserted-by":"crossref","first-page":"194S","DOI":"10.1177\/1076029618802364","article-title":"Laboratory assessment of the anticoagulant activity of Apixaban in patients with Nonvalvular atrial fibrillation","volume":"24","author":"Kyriakou","year":"2018","journal-title":"Clinical and Applied Thrombosis\/Hemostasis: Official Journal of the International Academy of Clinical and Applied Thrombosis\/Hemostasis"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109102_bb0710","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.thromres.2006.05.008","article-title":"Effect of substrate and fibrin polymerization inhibitor on determination of plasma thrombin generation in vitro","volume":"119","author":"Lau","year":"2007","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.pharmthera.2026.109102_bb0715","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehag337","article-title":"Asundexian and apixaban exert differential effects on thrombin generation: Insights from OCEANIC-AF","author":"Leader","year":"2026","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109102_bb0720","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"The New England Journal of Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109102_bb0725","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active Cancer: A randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109102_bb0730","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jcin.2014.06.014","article-title":"Direct oral anticoagulants: New drugs and new concepts","volume":"7","author":"Levy","year":"2014","journal-title":"JACC. Cardiovascular Interventions"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109102_bb0735","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/MBC.0000000000000178","article-title":"Effects of a plasma-derived C1 esterase inhibitor on hemostatic activation, clot formation, and thrombin generation","volume":"25","author":"Levy","year":"2014","journal-title":"Blood Coagulation & Fibrinolysis"},{"issue":"9508125","key":"10.1016\/j.pharmthera.2026.109102_bb0740","article-title":"The comparison of therapeutic efficacy between dabigatran versus warfarin in patients with Nonvalvular atrial fibrillation","volume":"27","author":"Li","year":"2021","journal-title":"Clinical and Applied Thrombosis\/Hemostasis: Official Journal of the International Academy of Clinical and Applied Thrombosis\/Hemostasis"},{"key":"10.1016\/j.pharmthera.2026.109102_bb0745","article-title":"Patients with multiple myeloma have a disbalanced whole blood thrombin generation profile","volume":"9","author":"Li","year":"2022","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109102_bb0750","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1055\/s-0038-1647337","article-title":"The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma","volume":"64","author":"Lindhout","year":"1990","journal-title":"Thrombosis and Haemostasis"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109102_bb0755","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/bcp.12719","article-title":"Exposure-response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation","volume":"80","author":"Lip","year":"2015","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109102_bb0760","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2147\/DDDT.S488414","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of Milvexian in healthy Chinese adults","volume":"19","author":"Luo","year":"2025","journal-title":"Drug Design, Development and Therapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109102_bb0765","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/jth.15589","article-title":"Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa","volume":"20","author":"Maag","year":"2022","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb0770","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/jcp.6.1.3","article-title":"A thrombin generation test; the application in haemophilia and thrombocytopenia","volume":"6","author":"Macfarlane","year":"1953","journal-title":"Journal of Clinical Pathology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb0775","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jtha.2023.09.015","article-title":"Effect of factor XI inhibition on tumor cell-induced coagulation activation","volume":"22","author":"M\u00e4der","year":"2024","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109102_bb0780","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8111990","article-title":"Rivaroxaban effects illustrate the underestimated importance of activated platelets in thrombin generation assessed by calibrated automated thrombography","volume":"8","author":"Makhoul","year":"2019","journal-title":"Journal of Clinical Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb0785","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2002-01-0290","article-title":"Factor V: A combination of Dr Jekyll and Mr Hyde","volume":"101","author":"Mann","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109102_bb0790","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/ijlh.13618","article-title":"Plasma levels do not predict thrombin generation in patients taking direct oral anticoagulants","volume":"43","author":"Metze","year":"2021","journal-title":"International Journal of Laboratory Hematology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb0795","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/rth2.12332","article-title":"Inhibition of thrombin generation 12 hours after intake of direct oral anticoagulants","volume":"4","author":"Metze","year":"2020","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2026.109102_bb0800","article-title":"Measuring Direct Oral Anticoagulant (DOAC) levels: Applications, limitations, and future directions","author":"Mithoowani","year":"2025","journal-title":"International Journal of Laboratory Hematology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb0805","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clinical Pharmacokinetics"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb0810","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/bjh.14003","article-title":"Heavy menstrual bleeding on rivaroxaban - comparison with Apixaban","volume":"176","author":"Myers","year":"2017","journal-title":"British Journal of Haematology"},{"issue":"52","key":"10.1016\/j.pharmthera.2026.109102_bb0815","doi-asserted-by":"crossref","first-page":"50445","DOI":"10.1074\/jbc.M208223200","article-title":"Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. II. Effects on fibrinolysis","volume":"277","author":"Nagashima","year":"2002","journal-title":"The Journal of Biological Chemistry"},{"issue":"52","key":"10.1016\/j.pharmthera.2026.109102_bb0820","doi-asserted-by":"crossref","first-page":"50439","DOI":"10.1074\/jbc.M208222200","article-title":"Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation","volume":"277","author":"Nagashima","year":"2002","journal-title":"The Journal of Biological Chemistry."},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109102_bb0825","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.jtha.2023.02.031","article-title":"Predictive value for increased activated factor XI activity in acute venous thromboembolism","volume":"21","author":"Nagy","year":"2023","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2026.109102_bb0830","series-title":"Primary thromboprophylaxis in patients with malignancy and central venous catheters: A randomized controlled trial (TRIM-Line). ClnicalTrials.gov identifier: NCFT05029063","author":"National Library of Medicine (US)","year":"2021"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109102_bb0835","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2471\/BLT.20.278473","article-title":"Global access to affordable direct oral anticoagulants","volume":"99","author":"Neumann","year":"2021","journal-title":"Bulletin of the World Health Organization"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb0840","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00441-023-03816-z","article-title":"The benefits and pitfalls of machine learning for biomarker discovery","volume":"394","author":"Ng","year":"2023","journal-title":"Cell and Tissue Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb0845","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/jth.15287","article-title":"Recommendations for the measurement of thrombin generation: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"19","author":"Ninivaggi","year":"2021","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2026.109102_bb0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.123157","article-title":"Factor XI inhibitors - rising stars in anti-thrombotic therapy?","volume":"464","author":"Nolte","year":"2024","journal-title":"Journal of the Neurological Sciences"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109102_bb0855","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0091270009351883","article-title":"Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers","volume":"50","author":"Ogata","year":"2010","journal-title":"Journal of Clinical Pharmacology"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109102_bb0860","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/j.1538-7836.2010.03917.x","article-title":"Anticoagulation by factor Xa inhibitors","volume":"8","author":"Orfeo","year":"2010","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109102_bb0865","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027852","article-title":"Anticoagulants and the propagation phase of thrombin generation","volume":"6","author":"Orfeo","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb0870","first-page":"e72","article-title":"ACC\/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"143","author":"Otto","year":"2020","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109102_bb0875","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1182\/bloodadvances.2024013126","article-title":"More early bleeds associated with high baseline direct oral anticoagulant levels in atrial fibrillation: The MAS study","volume":"8","author":"Palareti","year":"2024","journal-title":"Blood Advances"},{"key":"10.1016\/j.pharmthera.2026.109102_bb0880","series-title":"Evaluating evidence of mechanisms in medicine: Principles and procedures","author":"Parkkinen","year":"2018"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109102_bb0885","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"The New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109102_bb0890","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.jtha.2025.03.011","article-title":"Effect of direct oral anticoagulants in cirrhosis: An in vitro study","volume":"23","author":"Pereira Portela","year":"2025","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"0326377","key":"10.1016\/j.pharmthera.2026.109102_bb0895","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.thromres.2024.03.006","article-title":"Intrinsic coagulant potential modulates anticoagulant efficacy of rivaroxaban","volume":"237","author":"Pereira Portela","year":"2024","journal-title":"Thrombosis Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109102_bb0900","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/cts.13148","article-title":"First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor","volume":"15","author":"Perera","year":"2022","journal-title":"Clinical and Translational Science"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109102_bb0905","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/jth.12591","article-title":"Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo","volume":"12","author":"Perzborn","year":"2014","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb0910","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/MBC.0000000000000907","article-title":"Effects of rivaroxaban and dabigatran on global hemostasis in patients with atrial fibrillation","volume":"31","author":"Petkovic","year":"2020","journal-title":"Blood Coagulation & Fibrinolysis: an International Journal in Haemostasis and Thrombosis"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb0915","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/ijlh.13721","article-title":"Influence of direct oral anticoagulants on thrombin generation on Ceveron TGA","volume":"44","author":"Pfrepper","year":"2022","journal-title":"International Journal of Laboratory Hematology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb0920","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/rth2.12340","article-title":"Direct oral anticoagulant plasma levels and thrombin generation on ST genesia system","volume":"4","author":"Pfrepper","year":"2020","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"10333","key":"10.1016\/j.pharmthera.2026.109102_bb0925","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb0930","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus Apixaban in patients with atrial fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109102_bb0935","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2014-12-616565","article-title":"Sample conditions determine the ability of thrombin generation parameters to identify bleeding phenotype in FXI deficiency","volume":"126","author":"Pike","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109102_bb0940","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1001\/jama.2015.59","article-title":"Are new oral anticoagulant dosing recommendations optimal for all patients?","volume":"313","author":"Powell","year":"2015","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.pharmthera.2026.109102_bb0945","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1001\/jama.2015.5754","article-title":"Dosing recommendations for new oral anticoagulants--reply","volume":"313","author":"Powell","year":"2015","journal-title":"JAMA"},{"issue":"44","key":"10.1016\/j.pharmthera.2026.109102_bb0950","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1093\/eurheartj\/ehaf194","article-title":"2025 ESC\/EACTS guidelines for the management of valvular heart disease: Developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"46","author":"Praz","year":"2025","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109102_bb0955","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171486","article-title":"Differential inhibitory action of apixaban on platelet and fibrin components of forming thrombi: Studies with circulating blood and in a platelet-based model of thrombin generation","volume":"12","author":"Pujadas-Mestres","year":"2017","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109102_bb0960","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109102_bb0965","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.thromres.2014.11.017","article-title":"Comparison of methods to determine rivaroxaban anti-factor Xa activity","volume":"135","author":"Rathbun","year":"2015","journal-title":"Thrombosis Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb0970","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: The RE-LY trial (randomized evaluation of long-term anticoagulation therapy)","volume":"63","author":"Reilly","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109102_bb0975","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/MBC.0000000000000678","article-title":"Thrombin generation estimates the anticoagulation effect of direct oral anticoagulants with significant interindividual variability observed","volume":"29","author":"Rigano","year":"2018","journal-title":"Blood Coagulation & Fibrinolysis"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb0980","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/ijlh.12668","article-title":"A comparative study using thrombin generation and three different INR methods in patients on vitamin K antagonist treatment","volume":"39","author":"Riva","year":"2017","journal-title":"International Journal of Laboratory Hematology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109102_bb0985","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.phrs.2008.12.003","article-title":"Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs?","volume":"59","author":"Robert","year":"2009","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2026.109102_bb0990","article-title":"Factor XI and atrial fibrillation: A mismatched pairing?","volume":"20","author":"Rocca","year":"2025","journal-title":"European Cardiology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109102_bb0995","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.thromres.2015.08.009","article-title":"Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin","volume":"136","author":"Rousseau","year":"2015","journal-title":"Thrombosis Research"},{"issue":"9984","key":"10.1016\/j.pharmthera.2026.109102_bb1000","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/S0140-6736(14)61943-7","article-title":"Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial","volume":"385","author":"Ruff","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109102_bb1005","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1097\/ALN.0000000000000255","article-title":"Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation","volume":"120","author":"van Ryn","year":"2014","journal-title":"Anesthesiology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb1010","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/rth2.12120","article-title":"Comparison of antithrombin-dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots","volume":"2","author":"Salta","year":"2018","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"Supplement 1","key":"10.1016\/j.pharmthera.2026.109102_bb1015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1055\/s-0028-1086087","article-title":"Effect of Argatroban versus recombinant hirudin on tissue-factor-mediated thrombin generation: An in vitro study","volume":"34","author":"Samama","year":"2008","journal-title":"Seminars in Thrombosis and Hemostasis"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109102_bb1020","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1111\/j.1538-7836.2007.02753.x","article-title":"Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants","volume":"5","author":"Samama","year":"2007","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb1025","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1160\/TH09-03-0176","article-title":"Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor","volume":"103","author":"Samama","year":"2010","journal-title":"Thrombosis and Haemostasis"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb1030","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.thromres.2011.07.026","article-title":"In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux","volume":"129","author":"Samama","year":"2012","journal-title":"Thrombosis Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb1035","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1538-7836.2010.03767.x","article-title":"Severe hemophilia with mild bleeding phenotype: Molecular characterization and global coagulation profile","volume":"8","author":"Santagostino","year":"2010","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"10\u221213","key":"10.1016\/j.pharmthera.2026.109102_bb1040","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0039-128X(03)00139-9","article-title":"Progestin-regulated expression of tissue factor in decidual cells: Implications in endometrial hemostasis, menstruation and angiogenesis","volume":"68","author":"Schatz","year":"2003","journal-title":"Steroids"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109102_bb1045","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1160\/TH09-06-0396","article-title":"Impaired thrombin generation and fibrin clot formation in patients with dilutional coagulopathy during major surgery","volume":"103","author":"Schols","year":"2010","journal-title":"Thrombosis and Haemostasis"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109102_bb1050","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1161\/CIRCULATIONAHA.113.003191","article-title":"Factor Xa activation of factor V is of paramount importance in initiating the coagulation system: Lessons from a tick salivary protein","volume":"128","author":"Schuijt","year":"2013","journal-title":"Circulation"},{"issue":"0326377","key":"10.1016\/j.pharmthera.2026.109102_bb1055","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.thromres.2015.12.023","article-title":"Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation","volume":"138","author":"Semeraro","year":"2016","journal-title":"Thrombosis Research"},{"issue":"15","key":"10.1016\/j.pharmthera.2026.109102_bb1060","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2513880","article-title":"Asundexian for secondary stroke prevention","volume":"394","author":"Sharma","year":"2026","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb1065","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","article-title":"Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): A phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"23","author":"Sharma","year":"2024","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2026.109102_bb1070","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2026.100135","article-title":"Thrombin generation and the pharmacodynamics of parenteral anticoagulants","author":"Shaw","year":"2026","journal-title":"Pharmacy Review"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109102_bb1075","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1016\/j.jtha.2025.08.003","article-title":"Direct oral anticoagulant (DOAC) levels, bleeding, and breakthrough thrombosis: Fog of war","volume":"23","author":"Shaw","year":"2025","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2026.109102_bb1080","article-title":"DOAC-associated bleeding, hemostatic strategies, and thrombin generation assays - a review of the literature","author":"Shaw","year":"2022","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109102_bb1085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0293632","article-title":"Thrombin generation, bleeding and hemostasis in humans: Protocol for a scoping review of the literature","volume":"18","author":"Shaw","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2026.109102_bb1090","article-title":"Influence of direct oral anticoagulant levels and thrombin generation on postoperative bleeding [SONAR]: A nested case\u2013control study","author":"Shaw","year":"2025","journal-title":"Thrombosis and Haemostasis"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb1095","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.038782","article-title":"Thrombosis, translational medicine, and biomarker research: Moving the needle","volume":"14","author":"Shaw","year":"2025","journal-title":"Journal of the American Heart Association"},{"issue":"38","key":"10.1016\/j.pharmthera.2026.109102_bb1100","doi-asserted-by":"crossref","first-page":"11316","DOI":"10.1021\/bi0342923","article-title":"Heparin inhibits the intrinsic tenase complex by interacting with an exosite on factor IXa","volume":"42","author":"Sheehan","year":"2003","journal-title":"Biochemistry"},{"issue":"10357","key":"10.1016\/j.pharmthera.2026.109102_bb1105","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-stroke): An international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"issue":"9508125","key":"10.1016\/j.pharmthera.2026.109102_bb1110","article-title":"Factor Xa inhibitory profile of apixaban, betrixaban, edoxaban, and rivaroxaban does not fully reflect their biologic spectrum","volume":"25","author":"Siddiqui","year":"2019","journal-title":"Clinical and Applied Thrombosis\/Hemostasis: Official Journal of the International Academy of Clinical and Applied Thrombosis\/Hemostasis"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109102_bb1115","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1111\/jth.14541","article-title":"Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability","volume":"17","author":"Siguret","year":"2019","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2026.109102_bb1120","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.talanta.2017.12.055","article-title":"Thrombodynamics, a new global coagulation test: Measurement of heparin efficiency","volume":"180","author":"Sinauridze","year":"2018","journal-title":"Talanta"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109102_bb1125","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1055\/s-0038-1657772","article-title":"Betrixaban: Impact on routine and specific coagulation assays-a practical laboratory guide","volume":"118","author":"Siriez","year":"2018","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2026.109102_bb1130","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.thromres.2020.04.020","article-title":"VE-1902-a direct thrombin inhibitor with reversible covalent mechanism of action shows efficacy with reduced bleeding in rodent models of thrombosis","volume":"190","author":"Sivaraja","year":"2020","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.pharmthera.2026.109102_bb1135","doi-asserted-by":"crossref","DOI":"10.1016\/j.tru.2024.100175","article-title":"Plasma thrombin generation in the presence of TIX-5 may contribute significantly to a prediction model for major bleeding in patients on VKA anticoagulant therapy","volume":"15","author":"Sol-Maag","year":"2024","journal-title":"Thrombosis Update"},{"key":"10.1016\/j.pharmthera.2026.109102_bb1140","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2025.109384","article-title":"Thrombin generation assay in venous thromboembolism: A scoping review","volume":"252","author":"Souza","year":"2025","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.pharmthera.2026.109102_bb1145","series-title":"Update on Phase 3 Librexia ACS Trial [Internet]","author":"Squibb","year":"2025"},{"issue":"21","key":"10.1016\/j.pharmthera.2026.109102_bb1150","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"The New England Journal of Medicine"},{"issue":"21","key":"10.1016\/j.pharmthera.2026.109102_bb1155","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"The New England Journal of Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109102_bb1160","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1055\/a-2497-4213","article-title":"Real-time imaging of platelet-initiated plasma clot formation and lysis unveils distinct impacts of anticoagulants","volume":"125","author":"Suzuki","year":"2025","journal-title":"Thrombosis and Haemostasis"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb1165","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1213\/01.ANE.0000134685.75813.EB","article-title":"The effects of argatroban on thrombin generation and hemostatic activation in vitro","volume":"99","author":"Tanaka","year":"2004","journal-title":"Anesthesia and Analgesia"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb1170","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1213\/01.ane.0000278868.23814.3b","article-title":"Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin","volume":"105","author":"Tanaka","year":"2007","journal-title":"Anesthesia and Analgesia"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb1175","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/00365513.2024.2369993","article-title":"Effects of dabigatran, rivaroxaban, and apixaban on fibrin network permeability, thrombin generation, and fibrinolysis","volume":"84","author":"Taune","year":"2024","journal-title":"Scandinavian Journal of Clinical and Laboratory Investigation"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109102_bb1180","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109102_bb1185","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/jth.14457","article-title":"Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants","volume":"17","author":"Testa","year":"2019","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109102_bb1190","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1182\/bloodadvances.2023012408","article-title":"Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study","volume":"8","author":"Testa","year":"2024","journal-title":"Blood Advances"},{"key":"10.1016\/j.pharmthera.2026.109102_bb1195","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.thromres.2015.12.001","article-title":"Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics","volume":"137","author":"Testa","year":"2016","journal-title":"Thrombosis Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109102_bb1200","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1111\/jth.15439","article-title":"First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa","volume":"19","author":"Thomas","year":"2021","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb1205","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/jth.15248","article-title":"The relationship between DOAC levels and clinical outcomes: The measures tell the tale-response from original authors Lijfering et al.","volume":"19","author":"Toorop","year":"2021","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb1210","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/jth.15563","article-title":"Inter- and intra-individual concentrations of direct oral anticoagulants: The KIDOAC study","volume":"20","author":"Toorop","year":"2022","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"22","key":"10.1016\/j.pharmthera.2026.109102_bb1215","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics14222553","article-title":"Comparative investigation of Thromboelastometry and thrombin generation for patients receiving direct Oral anticoagulants or vitamin K antagonists","volume":"14","author":"Tripodi","year":"2024","journal-title":"Diagnostics"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109102_bb1220","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1538-7836.2008.03018.x","article-title":"High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism","volume":"6","author":"Tripodi","year":"2008","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109102_bb1225","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.thromres.2015.03.032","article-title":"How the direct oral anticoagulant apixaban affects thrombin generation parameters","volume":"135","author":"Tripodi","year":"2015","journal-title":"Thrombosis Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109102_bb1230","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102160","article-title":"New insight into the traditional model of the coagulation cascade and its regulation: Illustrated review of a three-dimensional view","volume":"7","author":"Troisi","year":"2023","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb1235","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1160\/TH08-07-0460","article-title":"A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)","volume":"101","author":"Turpie","year":"2009","journal-title":"Thrombosis and Haemostasis"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb1240","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1160\/th14-04-0346","article-title":"Organ-specific bleeding patterns of anticoagulant therapy: Lessons from clinical trials","volume":"112","author":"Vanassche","year":"2014","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2026.109102_bb1245","series-title":"Chapter 3 - developing a protocol for observational comparative effectiveness research: A user\u2019s guide. AHRQ publication no. 12(13)-EHC099","author":"Varadhan","year":"2013"},{"key":"10.1016\/j.pharmthera.2026.109102_bb1250","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.thromres.2024.03.001","article-title":"Asundexian in atrial fibrillation: Can pharmacodynamic data explain the failure?","volume":"236","author":"Vassart","year":"2024","journal-title":"Thrombosis Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb1255","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.102950","article-title":"Impact of asundexian on a panel of coagulation assays","volume":"9","author":"Vassart","year":"2025","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb1260","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/ijlh.13836","article-title":"Monitoring of heparin therapy beyond the anti-Xa activity assay: Evaluation of a thrombin generation assay","volume":"44","author":"Vermeiren","year":"2022","journal-title":"International Journal of Laboratory Hematology"},{"issue":"01","key":"10.1016\/j.pharmthera.2026.109102_bb1265","first-page":"049","article-title":"Reshaping anticoagulation: Factor XI inhibition in thrombosis management","volume":"44","author":"Verstraete","year":"2023","journal-title":"Hamostaseologie"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109102_bb1270","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1111\/jth.15075","article-title":"Effect of myeloperoxidase on the anticoagulant activity of low molecular weight heparin and rivaroxaban in an in vitro tumor model","volume":"18","author":"Voigtlaender","year":"2020","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109102_bb1275","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/j.1538-7836.2010.03822.x","article-title":"The paradoxical stimulation by a reversible thrombin inhibitor of thrombin generation in plasma measured with thrombinography is caused by alpha-macroglobulin-thrombin","volume":"8","author":"Wagenvoord","year":"2010","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109102_bb1280","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/MBC.0000000000000509","article-title":"An in-vitro evaluation of direct thrombin inhibitor and factor Xa inhibitor on tissue factor-induced thrombin generation and platelet aggregation: A comparison of dabigatran and rivaroxaban","volume":"27","author":"Wan","year":"2016","journal-title":"Blood Coagulation & Fibrinolysis: an International Journal in Haemostasis and Thrombosis"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109102_bb1285","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/ijlh.14020","article-title":"DOAC-stop can remove direct oral anticoagulants and allow analysis by global coagulation assays","volume":"45","author":"Wang","year":"2023","journal-title":"International Journal of Laboratory Hematology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb1290","first-page":"830","article-title":"Bivalirudin","volume":"99","author":"Warkentin","year":"2008","journal-title":"Thrombosis and Haemostasis"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109102_bb1295","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1172\/JCI114723","article-title":"Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors","volume":"86","author":"Weitz","year":"1990","journal-title":"The Journal of Clinical Investigation"},{"issue":"23","key":"10.1016\/j.pharmthera.2026.109102_bb1300","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"The New England Journal of Medicine"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109102_bb1305","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1055\/s-0040-1713752","article-title":"In vitro evaluation of pro- and anticoagulant drugs in children with end-stage liver disease undergoing liver transplantation","volume":"120","author":"Werner","year":"2020","journal-title":"Thrombosis and Haemostasis"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb1310","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1055\/s-0038-1656024","article-title":"The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability","volume":"77","author":"Wielders","year":"1997","journal-title":"Thrombosis and Haemostasis"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb1315","first-page":"155","article-title":"In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate","volume":"98","author":"Wienen","year":"2007","journal-title":"Thrombosis and Haemostasis"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb1320","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jtha.2023.12.037","article-title":"Altered whole blood thrombin generation and hyperresponsive platelets in patients with pancreatic cancer","volume":"22","author":"Willems","year":"2024","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2026.109102_bb1325","article-title":"Risk of first venous thrombosis by comparing different thrombin generation assay conditions: Results from the MEGA case-control study","volume":"9","author":"Winckers","year":"2025","journal-title":"TH Open"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb1330","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3810\/hp.2013.02.1009","article-title":"Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay","volume":"41","author":"Wong","year":"2013","journal-title":"Hospital Practice"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109102_bb1335","first-page":"378","article-title":"Thrombin generation increasing with age and decreasing with use of heparin indicated by calibrated automated thrombogram conducted in Chinese","volume":"27","author":"Wu","year":"2014","journal-title":"Biomedical and Environmental Sciences"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109102_bb1340","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1055\/s-0038-1646904","article-title":"The relative importance of the factors II, VII, IX and X for the prothrombinase activity in plasma of orally anticoagulated patients","volume":"62","author":"Xi","year":"1989","journal-title":"Thrombosis and Haemostasis"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109102_bb1345","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/MBC.0b013e32835e4219","article-title":"Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro","volume":"24","author":"Xu","year":"2013","journal-title":"Blood Coagulation & Fibrinolysis"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109102_bb1350","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1182\/blood.2025030466","article-title":"Fibrin as a thrombin sink: A factor retaining a thrombus in the stillness phase","volume":"148","author":"Yakusheva","year":"2026","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb1355","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1160\/TH13-12-1047","article-title":"Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits","volume":"112","author":"Yau","year":"2014","journal-title":"Thrombosis and Haemostasis"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109102_bb1360","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1111\/bcp.16211","article-title":"Plasma apixaban concentrations and thrombin generation assay parameters in response to dose reduction for atrial fibrillation","volume":"90","author":"Yeo","year":"2024","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"101170508","key":"10.1016\/j.pharmthera.2026.109102_bb1365","article-title":"Effects of milvexian alone or with heparin on catheter-induced clotting and thrombin generation","author":"Yin","year":"2025","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"20","key":"10.1016\/j.pharmthera.2026.109102_bb1370","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109102_bb1375","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1160\/TH14-07-0591","article-title":"Assays of fibrin network properties altered by VKAs in atrial fibrillation - importance of using an appropriate coagulation trigger","volume":"113","author":"Zabczyk","year":"2015","journal-title":"Thrombosis and Haemostasis"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109102_bb1380","first-page":"166","article-title":"Edoxaban administration following enoxaparin: A pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects","volume":"108","author":"Zahir","year":"2012","journal-title":"Thrombosis and Haemostasis"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109102_bb1385","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072018","article-title":"Delayed thrombin generation is associated with minor bleedings in venous thromboembolism patients on rivaroxaban: Usefulness of calibrated automated thrombography","volume":"9","author":"Zalewski","year":"2020","journal-title":"Journal of Clinical Medicine"},{"key":"10.1016\/j.pharmthera.2026.109102_bb1390","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bbrep.2015.11.011","article-title":"Exploring potential anticoagulant drug formulations using thrombin generation test","volume":"5","author":"Zavyalova","year":"2016","journal-title":"Biochemistry and Biophysics Reports"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109102_bb1395","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/MBC.0000000000001320","article-title":"Protein S contributes to the paradoxical increase in thrombin generation by low-dose dabigatran in the presence of thrombomodulin","volume":"35","author":"Zhang","year":"2024","journal-title":"Blood Coagulation & Fibrinolysis: an International Journal in Haemostasis and Thrombosis"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109102_bb1400","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1055\/s-0038-1672183","article-title":"Calibrated automated thrombinography (CAT), a tool to identify patients at risk of bleeding during anticoagulant therapy: A systematic review","volume":"2","author":"Zwaveling","year":"2018","journal-title":"TH Open: Companion Journal to Thrombosis and Haemostasis"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T20:24:55Z","timestamp":1788726295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725826001294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":280,"alternative-id":["S0163725826001294"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109102","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombin generation and the pharmacodynamics of oral anticoagulants","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109102"}}